Quoin Pharmaceuticals Ltd (QNRX) - Market Value to Book Value Ratio

Amid intense competition in the orphan drug segment, the GURU.Markets system provides a chart showing the market cap's multiple over book value for Quoin Pharmaceuticals (QNRX). The value 2.12 reflects the metric's baseline, linking it to the calibration precision of filling lines at contract manufacturing plants and future revenues from therapies for rare dermatological pathologies, including Netherton syndrome.

Quoin Pharmaceuticals operates in the high-tech segment of rare dermatological pathology therapy. By analyzing the historical relationship between market cap and book value, one can assess the market premium over the value of net assets. This ratio measures the gap between the exchange valuation and actual capital, determining the investment's margin of safety. The monopoly status of orphan drugs justifies the premium, but a sharp increase signals that the asset is overbought. A decrease in this metric enhances the defensive qualities of the asset.